Verastem, Inc, a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone781-292-4200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$26.72 million
Profitability
Miscellaneous
Employees169
Next Earnings Date10/29/2019 (Confirmed)
OptionableOptionable
Verastem (NASDAQ:VSTM) Frequently Asked Questions
What is Verastem's stock symbol?
Verastem trades on the NASDAQ under the ticker symbol "VSTM."
How were Verastem's earnings last quarter?
Verastem Inc (NASDAQ:VSTM) released its quarterly earnings results on Thursday, August, 1st. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.49) by $0.03. The biopharmaceutical company earned $3.14 million during the quarter, compared to the consensus estimate of $2.22 million. Verastem had a negative return on equity of 118.53% and a negative net margin of 526.42%. View Verastem's Earnings History.
When is Verastem's next earnings date?
How can I listen to Verastem's earnings call?
Verastem will be holding an earnings conference call on Tuesday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for VSTM?
6 analysts have issued 12 month target prices for Verastem's shares. Their predictions range from $2.50 to $9.00. On average, they anticipate Verastem's stock price to reach $5.75 in the next year. This suggests a possible upside of 408.8% from the stock's current price. View Analyst Price Targets for Verastem.
What is the consensus analysts' recommendation for Verastem?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Verastem.
What are Wall Street analysts saying about Verastem stock?
Here are some recent quotes from research analysts about Verastem stock:
- 1. According to Zacks Investment Research, "Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. " (7/13/2019)
- 2. HC Wainwright analysts commented, "We maintain our Buy rating of VSTM and lower our 12-month price target to $2.50 per share, down from $10.00. We derive our price target based on the average of two valuation methods: (1) price-sales multiple analysis applying an 8x multiple to our 2025 sales estimate discounted at 12%; and (2) price-earnings multiple analysis applying an 18x multiple to our 2025 estimated earnings discounted at 12%. (1) commercial; (2) clinical; (3) financial; (4) regulatory; and (5) intellectual property." (5/10/2019)
Has Verastem been receiving favorable news coverage?
Media headlines about VSTM stock have trended somewhat positive this week, according to InfoTrie. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Verastem earned a daily sentiment score of 2.0 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Verastem.
Who are some of Verastem's key competitors?
Some companies that are related to Verastem include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Array Biopharma (ARRY), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS).
What other stocks do shareholders of Verastem own?
Who are Verastem's key executives?
Verastem's management team includes the folowing people:
- Mr. Robert Forrester, Pres, CEO & Director (Age 55)
- Mr. Robert E. Gagnon, Chief Financial Officer (Age 45)
- Mr. Joseph M. Lobacki, Exec. VP & Chief Commercial Officer (Age 61)
- Mr. Richard H. Aldrich M.B.A., Mba, Founder and Consultant (Age 65)
- Dr. Robert A. Weinberg, Co-Founder and Chair of Scientific Advisory Board
Who are Verastem's major shareholders?
Verastem's stock is owned by many different of institutional and retail investors. Top institutional investors include SeaCrest Wealth Management LLC (0.03%). Company insiders that own Verastem stock include Dan Paterson, Joseph M Lobacki, Michael Kauffman, Robert Forrester, Steven H Bloom and Timothy J Barberich. View Institutional Ownership Trends for Verastem.
Which institutional investors are selling Verastem stock?
How do I buy shares of Verastem?
Shares of VSTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Verastem's stock price today?
One share of VSTM stock can currently be purchased for approximately $1.13.
How big of a company is Verastem?
Verastem has a market capitalization of $83.78 million and generates $26.72 million in revenue each year. The biopharmaceutical company earns $-72,430,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. Verastem employs 169 workers across the globe.View Additional Information About Verastem.
What is Verastem's official website?
How can I contact Verastem?
Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The biopharmaceutical company can be reached via phone at 781-292-4200 or via email at [email protected]
MarketBeat Community Rating for Verastem (NASDAQ VSTM)
MarketBeat's community ratings are surveys of what our community members think about Verastem and other stocks. Vote "Outperform" if you believe VSTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VSTM will underperform the S&P 500 over the long term. You may vote once every thirty days.
